A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling

被引:9
作者
Asawa, Rosita R. [1 ]
Zakharov, Alexey [1 ]
Niehoff, Taylor [1 ]
Chitsaz, Ata [1 ]
Jadhav, Ajit [1 ]
Henderson, Mark J. [1 ]
Simeonov, Anton [1 ]
Martinez, Natalia J. [1 ]
机构
[1] NIH, Natl Ctr Advancing Translat Sci, 9800 Med Ctr Dr, Rockville, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HDAC1; qHTS; profiling; SplitLuc CETSA; NanoBRET; epigenetic compound library; target engagement; HISTONE DEACETYLASES; EXPRESSION; CANCER; FAMILY;
D O I
10.1177/2472555219883625
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Histone deacetylases (HDACs) are epigenetic modulators linked to diseases including cancer and neurodegeneration. Given their therapeutic potential, highly sensitive biochemical and cell-based profiling technologies have been developed to discover small-molecule HDAC inhibitors. Ultimately, the therapeutic action of these inhibitors is dependent on a physical engagement with their intended targets in cellular and tissue environments. Confirming target engagement in the cellular environment is particularly relevant for HDACs since they function as part of cell type-specific multiprotein complexes. Here we implemented two recently developed high-throughput target engagement technologies, NanoBRET and SplitLuc CETSA, to profile 349 compounds in the Epigenetic-Focused collection for HDAC1 binding. We found that the two HDAC1 target engagement assays correlated well with each other and with orthogonal activity-based assays, in particular those carried out in cellular environments rather than with isolated HDAC proteins. The assays detected a majority of the previously described HDAC1 inhibitors in the collection and, importantly, triaged HDAC inhibitors known to target other HDACs.
引用
收藏
页码:253 / 264
页数:12
相关论文
共 34 条
  • [1] Differential HDAC1/2 network analysis reveals a role for prefoldin/CCT in HDAC1/2 complex assembly
    Banks, Charles A. S.
    Miah, Sayem
    Adams, Mark K.
    Eubanks, Cassandra G.
    Thornton, Janet L.
    Florens, Laurence
    Washburn, Michael P.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [2] Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
    Bantscheff, Marcus
    Hopf, Carsten
    Savitski, Mikhail M.
    Dittmann, Antje
    Grandi, Paola
    Michon, Anne-Marie
    Schlegl, Judith
    Abraham, Yann
    Becher, Isabelle
    Bergamini, Giovanna
    Boesche, Markus
    Delling, Manja
    Duempelfeld, Birgit
    Eberhard, Dirk
    Huthmacher, Carola
    Mathieson, Toby
    Poeckel, Daniel
    Reader, Valerie
    Strunk, Katja
    Sweetman, Gavain
    Kruse, Ulrich
    Neubauer, Gitte
    Ramsden, Nigel G.
    Drewes, Gerard
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (03) : 255 - U124
  • [3] jvenn: an interactive Venn diagram viewer
    Bardou, Philippe
    Mariette, Jerome
    Escudie, Frederic
    Djemiel, Christophe
    Klopp, Christophe
    [J]. BMC BIOINFORMATICS, 2014, 15
  • [4] Becher I, 2016, NAT CHEM BIOL, V12, P908, DOI [10.1038/NCHEMBIO.2185, 10.1038/nchembio.2185]
  • [5] Isoform-selective histone deacetylase inhibitors
    Bieliauskas, Anton V.
    Pflum, Mary Kay H.
    [J]. CHEMICAL SOCIETY REVIEWS, 2008, 37 (07) : 1402 - 1413
  • [6] Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192
    Boissinot, Marjorie
    Inman, Martyn
    Hempshall, Aiden
    James, Sally R.
    Gill, Jason H.
    Selby, Peter
    Bowen, David T.
    Grigg, Ronald
    Cockerill, Peter N.
    [J]. LEUKEMIA RESEARCH, 2012, 36 (10) : 1304 - 1310
  • [7] Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
    Chou, C. James
    Herman, David
    Gottesfeld, Joel M.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (51) : 35402 - 35409
  • [8] Multiple roles of HDAC inhibition in neurodegenerative conditions
    Chuang, De-Maw
    Leng, Yan
    Marinova, Zoya
    Kim, Hyeon-Ju
    Chiu, Chi-Tso
    [J]. TRENDS IN NEUROSCIENCES, 2009, 32 (11) : 591 - 601
  • [9] Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
    Delcuve, Genevieve P.
    Khan, Dilshad H.
    Davie, James R.
    [J]. CLINICAL EPIGENETICS, 2012, 4
  • [10] Histone Deacetylase Inhibitors as Anticancer Drugs
    Eckschlager, Tomas
    Plch, Johana
    Stiborova, Marie
    Hrabeta, Jan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)